Condition
Gastrointestinal Stromal Tumour
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting1
Unknown1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07124000Recruiting
DESTINY-PANTUMOUR04
NCT02365441Phase 2UnknownPrimary
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
NCT02009423Phase 3TerminatedPrimary
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Showing all 3 trials